reports
New Hypertension publication underscores aprocitentan’s potential in m...
New Hypertension publication underscores aprocitentan’s potential in managing hypertension patients with CKD New analysis from landmark Phase 3 PRECISION trial published in Hypertension highlights the renal-protective benefits of aprocitentan in addition to the marked reduction in blood pressure in a high-risk CKD population with difficult-to-control hypertension Allschwil, Switzerland – December 10, 2025Idorsia Ltd (SIX: IDIA) announced the publication of a new analysis from the landmark Phase 3 PRECISION study in Hypertension titled “”.1 The analysis examined the efficacy and safety of a...
Idorsia’s aprocitentan improved key prognostic indicators in patients ...
Idorsia’s aprocitentan improved key prognostic indicators in patients with difficult-to-control hypertension New analysis from landmark Phase 3 PRECISION trial published in the Journal of Hypertension highlights aprocitentan led to improvements in dipping pattern and BP load Findings reinforce the role of aprocitentan’s novel endothelin pathway mechanism in addressing significant medical need in difficult-to-control hypertension Allschwil, Switzerland – November 10, 2025Idorsia Ltd (SIX: IDIA) announced the publication of a new analysis from the landmark Phase 3 PRECISION study in the Jou...
Idorsia to present new aprocitentan insights at ASN Kidney Week & AHA ...
Idorsia to present new aprocitentan insights at ASN Kidney Week & AHA Scientific Sessions New analysis confirms reductions in blood pressure and albuminuria by aprocitentan in patients with true resistant hypertension and high cardiovascular risk – including chronic kidney disease Allschwil, Switzerland – November 05, 2025Idorsia Ltd (SIX: IDIA) shares that new analysis of the landmark Phase 3 PRECISION study of aprocitentan, Idorsia’s endothelin receptor antagonist, will be presented at the American Society of Nephrology (ASN) Kidney Week 2025, taking place in Houston, TX, November 5–9, 2...
Idorsia highlights very low real-world abuse potential of DORA class f...
Idorsia highlights very low real-world abuse potential of DORA class for insomnia treatment at WSC 2025 Analysis of the FAERS database shows that the real-world abuse potential of the DORA class is very low and markedly less than those seen for other scheduled and non-scheduled insomnia therapies Allschwil, Switzerland – September 8, 2025Idorsia Ltd (SIX: IDIA) presented real-world data from the FDA Adverse Event Reporting System (FAERS) at the World Sleep 2025, evaluating abuse-related adverse events for dual orexin receptor antagonists (DORAs) in comparison to other insomnia therapies....
Idorsia’s TRYVIO – First FDA-approved therapy to target the endothelin...
Idorsia’s TRYVIO – First FDA-approved therapy to target the endothelin pathway for systemic hypertension Allschwil, Switzerland – August 28, 2025Idorsia Ltd (SIX: IDIA) releases an outlining how TRYVIO™ (aprocitentan) – the first and only hypertension therapy targeting the endothelin pathway – fits into the treatment landscape for difficult-to-control hypertension. In addition, the company will host a live investor Q&A on September 8, 2025, following the American Heart Association's (AHA) Hypertension Scientific Sessions. TRYVIO is the first systemic hypertension treatment to target a n...
TRYVIO™ (aprocitentan) now included in ACC/AHA Clinical Practice Guide...
TRYVIO™ (aprocitentan) now included in ACC/AHA Clinical Practice Guidelines for the treatment of hypertension The updated recommendations now include TRYVIO™ (aprocitentan) – the first and only hypertension treatment targeting the endothelin pathway.Endothelin is upregulated in hypertension and is a fundamental mediator in patients whose hypertension is difficult-to-control.Hypertension remains a major global health issue, and the number one modifiable risk factor of early morbidity/mortality. Allschwil, Switzerland & Radnor, Pennsylvania – August 19, 2025Idorsia Ltd (SIX: IDIA) announces ...
The effect of aprocitentan for reducing blood pressure and proteinuria...
The effect of aprocitentan for reducing blood pressure and proteinuria in Black patients with resistant hypertension published in Hypertension Aprocitentan, on top of background therapy, showed clinically meaningful and durable blood pressure (BP) reduction and a decrease in proteinuria in Black patients with confirmed resistant hypertension Allschwil, Switzerland – April 9, 2025Idorsia Ltd (SIX: IDIA) today announced the publication of "” in the April edition of Hypertension1. The publication reports preplanned analyses of the efficacy, tolerability and safety of aprocitentan – Idorsia’s ...
US FDA approves an updated label for TRYVIO (aprocitentan) removing th...
US FDA approves an updated label for TRYVIO (aprocitentan) removing the REMS requirement Allschwil, Switzerland – April 9, 2025Idorsia Ltd (SIX: IDIA) today announced that the US Food & Drug Administration (FDA), after having released TRYVIO from its REMS (Risk Evaluation and Mitigation Strategy) requirement (), has now approved the updated label for TRYVIO™ (aprocitentan). TRYVIO is Idorsia’s dual endothelin receptor antagonist (ERA) indicated for the treatment of systemic hypertension in combination with other antihypertensives to lower blood pressure in patients who are not adequately co...
Idorsia and Viatris enter into a significant global research and devel...
Idorsia and Viatris enter into a significant global research and development collaboration Ad hoc announcement pursuant to Art. 53 LR Viatris and Idorsia will collaborate on the global development and commercialization of two Phase 3 assets, selatogrel and cenerimod.Idorsia to receive an upfront payment of USD 350 million, potential development and regulatory milestone payments, additional sales milestone payments and tiered royalties on annual net sales.Viatris and Idorsia will both contribute to the development costs for both programs.Includes future optionality to expand collaboration ...
Idorsia and Viatris enter into a significant global research and devel...
Idorsia and Viatris enter into a significant global research and development collaboration Ad hoc announcement pursuant to Art. 53 LR Viatris and Idorsia will collaborate on the global development and commercialization of two Phase 3 assets, selatogrel and cenerimod.Idorsia to receive an upfront payment of USD 350 million, potential development and regulatory milestone payments, additional sales milestone payments and tiered royalties on annual net sales.Viatris and Idorsia will both contribute to the development costs for both programs.Includes future optionality to expand collaboration ...
New Phase 3 data with aprocitentan for patients with resistant hyperte...
New Phase 3 data with aprocitentan for patients with resistant hypertension has been presented at the American Society of Nephrology Kidney Week 2023 Allschwil, Switzerland – November 3, 2023 Idorsia Ltd (SIX: IDIA) announced today that further data for aprocitentan, Idorsia’s investigational dual endothelin receptor antagonist for the treatment of patients with resistant hypertension, were presented as an oral presentation entitled “” by George Bakris, MD, at the American Society of Nephrology (ASN) Kidney Week 2023. Patients with hypertension can often successfully control their blood p...
New Phase 3 data with aprocitentan for patients with resistant hyperte...
New Phase 3 data with aprocitentan for patients with resistant hypertension has been presented at the American Society of Nephrology Kidney Week 2023 Allschwil, Switzerland – November 3, 2023 Idorsia Ltd (SIX: IDIA) announced today that further data for aprocitentan, Idorsia’s investigational dual endothelin receptor antagonist for the treatment of patients with resistant hypertension, were presented as an oral presentation entitled “” by George Bakris, MD, at the American Society of Nephrology (ASN) Kidney Week 2023. Patients with hypertension can often successfully control their blood p...
New Phase 3 data with aprocitentan for patients with resistant hyperte...
New Phase 3 data with aprocitentan for patients with resistant hypertension has been presented at the European Society of Hypertension Annual Meeting 2023 Allschwil, Switzerland – June 26, 2023 Idorsia Ltd (SIX: IDIA) today announced that further data for aprocitentan, Idorsia’s investigational dual endothelin receptor antagonist evaluating the treatment of patients with resistant hypertension, were presented as an oral presentation entitled “Effects of the dual endothelin antagonist aprocitentan on ambulatory blood pressure indices in patients with resistant hypertension – results from ...
New Phase 3 data with aprocitentan for patients with resistant hyperte...
New Phase 3 data with aprocitentan for patients with resistant hypertension has been presented at the European Society of Hypertension Annual Meeting 2023 Allschwil, Switzerland – June 26, 2023 Idorsia Ltd (SIX: IDIA) today announced that further data for aprocitentan, Idorsia’s investigational dual endothelin receptor antagonist evaluating the treatment of patients with resistant hypertension, were presented as an oral presentation entitled “Effects of the dual endothelin antagonist aprocitentan on ambulatory blood pressure indices in patients with resistant hypertension – results from ...
On World Sleep Day Idorsia highlights the publication of a global stud...
On World Sleep Day Idorsia highlights the publication of a global study on the economic and societal impact of chronic insomnia disorder Chronic insomnia disorder (CID) is a persistent medical condition that prevents sufferers from getting restorative sleep1-3; research on wider societal and indirect economic costs associated with CID have been limited to date1New report indicates annual lost productivity costs of $417 billion in GDP across working age populations in the countries of focus* and annual “hidden” intangible wellbeing losses of $239.5 billion1Reducing the impact of CID could re...
On World Sleep Day Idorsia highlights the publication of a global stud...
On World Sleep Day Idorsia highlights the publication of a global study on the economic and societal impact of chronic insomnia disorder Chronic insomnia disorder (CID) is a persistent medical condition that prevents sufferers from getting restorative sleep1-3; research on wider societal and indirect economic costs associated with CID have been limited to date1New report indicates annual lost productivity costs of $417 billion in GDP across working age populations in the countries of focus* and annual “hidden” intangible wellbeing losses of $239.5 billion1Reducing the impact of CID could re...
Idorsia submits a New Drug Application to the US FDA for aprocitentan ...
Idorsia submits a New Drug Application to the US FDA for aprocitentan for the treatment of patients with difficult-to-control hypertension The application includes data from the Phase 3 registration study of patients with resistant hypertension, where aprocitentan demonstrated a sustained blood pressure reduction over 48 weeks and was well-tolerated Allschwil, Switzerland – December 20, 2022 Idorsia Ltd (SIX: IDIA) today announced that it has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) seeking approval for aprocitentan, Idorsia’s investigational, nov...
Idorsia submits a New Drug Application to the US FDA for aprocitentan ...
Idorsia submits a New Drug Application to the US FDA for aprocitentan for the treatment of patients with difficult-to-control hypertension The application includes data from the Phase 3 registration study of patients with resistant hypertension, where aprocitentan demonstrated a sustained blood pressure reduction over 48 weeks and was well-tolerated Allschwil, Switzerland – December 20, 2022 Idorsia Ltd (SIX: IDIA) today announced that it has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) seeking approval for aprocitentan, Idorsia’s investigational, nov...
Long-term safety and tolerability results with daridorexant in patient...
Long-term safety and tolerability results with daridorexant in patients with insomnia disorder published in CNS Drugs Daridorexant, taken every night for up to 12 months, was well-tolerated with no signs of tolerance (loss of effect) or physical dependence, and no evidence of withdrawal or rebound insomnia upon treatment discontinuationExploratory efficacy endpoints show sustained improvements in nighttime sleep variables and daytime functioning Allschwil, Switzerland – December 12, 2022Idorsia Ltd (SIX: IDIA) today announced the publication of “” in CNS Drugs1. The publication reports the...
Long-term safety and tolerability results with daridorexant in patient...
Long-term safety and tolerability results with daridorexant in patients with insomnia disorder published in CNS Drugs Daridorexant, taken every night for up to 12 months, was well-tolerated with no signs of tolerance (loss of effect) or physical dependence, and no evidence of withdrawal or rebound insomnia upon treatment discontinuationExploratory efficacy endpoints show sustained improvements in nighttime sleep variables and daytime functioning Allschwil, Switzerland – December 12, 2022Idorsia Ltd (SIX: IDIA) today announced the publication of “” in CNS Drugs1. The publication reports the...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.